跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
在 國立成功大學 搜尋內容
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
查看斯高帕斯 (Scopus) 概要
陳 雅萍
Doctor
內科部
電子郵件
i5484128
gmail
com
h-index
863
引文
16
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2006
2025
每年研究成果
概覽
指紋
網路
研究成果
(50)
類似的個人檔案
(6)
指紋
查看啟用 Ya-Ping Chen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Poor Prognosis
54%
Multilocus Approach
50%
Lymphoma Therapy
50%
Thromboprophylaxis
50%
Typhlitis
50%
Refractory Myeloma
50%
Community-acquired
50%
Diffuse Large B-cell Lymphoma (DLBCL)
50%
Endoplasmic Reticulum Stress Response
50%
PLASMIC Score
50%
Dominant Expression
50%
Effusion
50%
Signal Regulatory Protein
50%
Iron Chelation Therapy
50%
Electrospray Ionization Mass Spectrometry
50%
Acutely Ill Patients
50%
Klebsiella Oxytoca
50%
Epidermal Growth Factor Receptor
50%
Aurora Kinase Inhibitor
50%
Fungal Pathogens
50%
Plasmacytoid Dendritic Cells
50%
High-risk Acute Leukemia
50%
Cancer Therapeutics-related Cardiac Dysfunction
50%
Endocarditis
50%
AURKC
50%
Mycobacterium Kansasii
50%
Clinical Specimens
50%
T315I mutation
50%
Glucosylceramide Synthase Inhibitor
50%
Aprepitant
50%
Cytoplasmic Lipid Droplet
50%
Aurora A
50%
Bruton Tyrosine Kinase Inhibitor
50%
Feeding Vessels
50%
Malignant Pleural Effusion
50%
Thymectomy
43%
Polymerase Chain Reaction
43%
Iron Chelation
33%
Virus Morphology
33%
Two-drug Combination
33%
Serotonin Receptor Antagonists
33%
ADAMTS13
31%
Myeloma
29%
Cytogenetic Findings
25%
9p24
25%
Human Herpesvirus 6 (HHV-6)
25%
Bone Marrow Examination
25%
Fever Syndromes
25%
Ki-67 Index
25%
Cytological Changes
25%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Cancer Therapy
88%
Malignant Neoplasm
75%
Aurora A Kinase
60%
Colorectal Carcinoma
55%
Glucose-6-Phosphate Dehydrogenase Deficiency
50%
Klebsiella oxytoca
50%
Polypyrrole
50%
Von Willebrand Factor Cleaving Proteinase
50%
Programmed Death 1 Ligand 1
50%
Sentinel Node
50%
Platelet Derived Growth Factor Alpha Receptor
50%
Natural Killer Cell Lymphoma
50%
Typhlitis
50%
Carcinogenicity
50%
Chelation Therapy
50%
Epidermal Growth Factor Receptor
50%
Breast Cancer
50%
Immunotherapy
50%
Upregulation
50%
Plasmacytoid Dendritic Cell
50%
Mycobacterium Avium-Intracellulare Infection
50%
Aprepitant
50%
Effusion
50%
Epithelial Cell
50%
Neoplasm
34%
Cervical Cancer
33%
Cancer Cell
33%
5-HT3 Antagonist
33%
Cancer
30%
Diseases
25%
Bone Marrow Examination
25%
Human Herpesvirus 6
25%
Docetaxel
25%
Messenger RNA
21%
Aurora Kinase Inhibitor
19%
Adipophilin
18%
Hemolytic Anemia
16%
Cancer Treatment
16%
Promoter Region
16%
Thyroid Carcinoma
16%
Cancer Cell Line
16%
Repressor Gene
16%
Myeloproliferative Disorder
16%
Spindle Checkpoint
16%
Antimycobacterial Agent
16%
Antiemetic Activity
16%
Chemotherapy-Induced Nausea and Vomiting
16%
NK1 Receptor Antagonist
16%
Phosphotransferase
16%
Biochemistry, Genetics and Molecular Biology
Myeloid
100%
Programmed Cell Death
56%
B Cell
50%
ADAMTS13
50%
Arginine Deiminase
50%
Iron Chelation
50%
Cancer Cell
50%
Stem Cell
50%
Allogeneic Hematopoietic Stem Cell Transplantation
50%
Natural Killer Cell
50%
Glycogen Synthase Kinase 3
50%
Ceramide Glucosyltransferase
50%
Platelet Derived Growth Factor Receptor Alpha
50%
Disease Free Survival
50%
Overall Survival
45%
Multivariate Analysis
25%
HOXA9
25%
Philadelphia Chromosome
25%
Argininosuccinate Synthase
22%
Arginine
16%
Promoter Region
16%
Messenger RNA
16%
Phlebotomy
16%
T Cell
16%
Phosphotransferase
16%
Transcriptional Repressor
16%
Kinase
16%
Spindle Checkpoint
16%
Carcinogenesis
16%
Activating Transcription Factor 6
14%
Case-Control Study
12%
Tumor Volume
12%
Survival Rate
12%
Ceramide
11%
CD47
8%
Rituximab
8%
XBP1
7%
DNA Damage-Inducible Transcript 3
7%
Chemotaxis
6%
Intermediate Risk Population
6%
Agar
6%
Mouse Model
6%
G2 Phase Cell Cycle Checkpoint
6%
Cell Viability
6%
CCL20
6%
Precursor
6%
Bioinformatics
6%
Stem Cell Marker
6%
Gene Expression Profiling
5%
RNA Sequencing
5%
